fluvoxamine and Alzheimer-Disease

Topics: Alzheimer Disease; Animals; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fluvoxamine; Humans; Mental Disorders; Neoplasms; Post-Acute COVID-19 Syndrome; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors

Topics: Acute Disease; Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cross-Over Studies; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male; Perphenazine; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Dementia, Multi-Infarct; Female; Fluvoxamine; Humans; Male; Tryptophan

Topics: Aged, 80 and over; Alzheimer Disease; Amnesia; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Fluvoxamine; Humans; Mental Disorders; Phenylpropionates; Pyrazoles; Sulfonamides

To report 3 cases of severe behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) with fluvoxamine treatment and to discuss the treatment implications for use of the drug.. An 83-year-old woman was diagnosed with AD. Before treatment, she showed sudden irritation and excitement. Her BEHAVE-AD score was 40. She was started on fluvoxamine and quetiapine. Eight weeks later, she was friendly and thankful towards the staff. Her BEHAVE-AD score was 10. The second case was a 79-year-old woman diagnosed with AD. Before treatment, she attempted to leave our hospital and wandered and shouted throughout the day. Her BEHAVE-AD score was 42. She was started on fluvoxamine, and the dosage was gradually increased. Eight weeks later, the shouting and excitement disappeared almost completely. Her BEHAVE-AD score was 13. The third case was a 79-year-old man diagnosed with AD. Before treatment, we put him in a private, locked room because he was extremely agitated and violent because of delusions. His BEHAVE-AD score was 42. He was started on fluvoxamine and sodium valproate. Eight weeks later, the delusion became mild and did not affect his mood or behavior. His BEHAVE-AD score at this point was 4.. Fluvoxamine was effective in controlling BPSD with AD. This finding shows that the pathophysiology of BPSD due to AD may occur because of a hyposerotonergic state in the brain.. These cases show that fluvoxamine appears to be effective in the control of BPSD with AD.

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Female; Fluvoxamine; Humans; Male; Selective Serotonin Reuptake Inhibitors

Mutant R406W human tau was originally identified in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and causes a hereditary tauopathy that clinically resembles Alzheimer's disease (AD). In the current study, we examined the performance of R406W transgenic (Tg) mice in the forced swimming test, a test with high predictivity of antidepressant efficacy in human depression, and found an enhancement of the immobility time. In contrast, the motor function and anxiety-related emotional response of R406W Tg mice were normal. Furthermore, a selective serotonin reuptake inhibitor (SSRI), fluvoxamine (100 mg/kg, p.o.), significantly reduced this enhancement of the immobility time, whereas a noradrenaline reuptake inhibitor, desipramine, had no effect. In an in vivo microdialysis study, R406W Tg mice exhibited a significantly decreased extracellular 5-hydroxyindoleacetic acid (5-HIAA) level in the frontal cortex and also exhibited a tendency toward a decreased extracellular 5-hydroxytryptamine (5-HT) level. Moreover, fluvoxamine, which reduced the enhancement of the immobility time, significantly increased the extracellular 5-HT level in R406W Tg mice. These results suggest that R406W Tg mice exhibit changes in depression-related behavior involving serotonergic neurons and provide an animal model for investigating AD with depression.

Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain Chemistry; Depressive Disorder; Disease Models, Animal; Extracellular Fluid; Fluvoxamine; Humans; Hydroxyindoleacetic Acid; Mice; Mice, Transgenic; Microdialysis; Motor Activity; Mutation; Neurons; Raphe Nuclei; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; tau Proteins; Up-Regulation

Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluvoxamine; Humans; Perphenazine; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome

To describe the effects of treatment with the selective serotonin reuptake inhibitor fluvoxamine on three patients with advanced dementia who developed a stereotypic movement disorder.. Three patients in a skilled nursing facility were referred by their primary physicians for psychiatric consultation to assist with the management of stereotypic behaviors. The patients received a standard medical, neurologic, and psychiatric workup for dementia. Two of the patients were diagnosed with dementia of the Alzheimer type and the other patient was diagnosed with vascular dementia. All three patients were started on fluvoxamine 25 mg/d; behaviors were monitored daily by the nursing staff and their primary care physicians and weekly by their psychiatrist using the Abnormal Involuntary Movement Scales. The dosage was titrated upward weekly to a maximum dosage of 150 mg/d.. Two patients showed complete resolution of their stereotypic behaviors by week 6. The third patient showed noticeable improvement with some residual movements after 8 weeks of treatment.. Fluvoxamine appeared effective in the control of stereotypic behaviors in three patients with advanced dementia.

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Fluvoxamine; Humans; Selective Serotonin Reuptake Inhibitors; Stereotyped Behavior